<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7533207\results\search\testTrace\results.xml">
  <result pre="a wide range of infectious diseases for which no specific" exact="treatment" post="is available. The use of convalescent plasma involves transfusing"/>
  <result pre="studies have shown the effects of convalescent plasma for the" exact="treatment" post="of severe coronavirus disease 2019 (COVID-19). In addition to"/>
  <result pre="serotherapy Plasma Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="infection" post="has become a global concern, and the World Health"/>
  <result pre="are few therapeutic agents that have been approved for the" exact="treatment" post="of COVID-19, and there are no vaccines [4]. Remdesivir"/>
  <result pre="convalescent plasma was used to treat patients with severe H1N1" exact="infection" post="requiring critical care [12]. A study with 93 participants"/>
  <result pre="critical care [12]. A study with 93 participants showed that" exact="treatment" post="of severe H1N1 2009 infection with convalescent plasma reduced"/>
  <result pre="with 93 participants showed that treatment of severe H1N1 2009" exact="infection" post="with convalescent plasma reduced respiratory tract viral load, serum"/>
  <result pre="with convalescent whole blood compared to those who received standard" exact="treatment" post="[13]. However, another nonrandomized study on Ebola virus disease"/>
  <result pre="Kong evaluated the efficacy of convalescent plasma therapy in the" exact="treatment" post="of patients with SARS in 2003 [15]. A higher"/>
  <result pre="suggested that donor plasma with a neutralization activity of a" exact="plaque reduction neutralization test" post="(PRNT) titer â‰¥1:80 should be used for convalescent plasma"/>
  <result pre="donor plasma with a neutralization activity of a plaque reduction" exact="neutralization test" post="(PRNT) titer â‰¥1:80 should be used for convalescent plasma"/>
  <result pre="convalescent plasma, previous experiences on convalescent plasma therapy for the" exact="treatment" post="of emerging infectious diseases provide us with important historical"/>
  <result pre="Several uncontrolled case series of convalescent plasma therapy for the" exact="treatment" post="of patients with COVID-19 have suggested a possible benefit"/>
  <result pre="clinical studies on the use of convalescent plasma as a" exact="treatment" post="option for COVID-19 are ongoing in many countries. As"/>
  <result pre="underlying lung injury associated with COVID-19 further complicates the differential" exact="diagnosis" post="of TACO and TRALI, and may increase the risk"/>
  <result pre="patients with COVID-19 have mild disease and recover with conservative" exact="treatment" post="only. Clinical studies on convalescent plasma therapy for COVID-19"/>
  <result pre="serological test for SARS-CoV-2 antibodies after recovery, if prior diagnostic" exact="testing" post="was not performed at the time that COVID-19 was"/>
  <result pre="days after being cured of COVID-19. Negative results of real-time" exact="reverse transcription polymerase chain reaction" post="for SARS-CoV-2 using a respiratory specimen should be confirmed"/>
  <result pre="being cured of COVID-19. Negative results of real-time reverse transcription" exact="polymerase chain reaction" post="for SARS-CoV-2 using a respiratory specimen should be confirmed"/>
  <result pre="suitable for a repeat donation of plasma. (4) Other donor" exact="screening" post="criteria, blood collection procedures, donor safety matters, and handling"/>
  <result pre="antibody titers, such as the PRNT, microneutralization assay, and pseudovirus" exact="neutralization assay," post="are not routinely performed in hospital settings. However, as"/>
  <result pre="Chemother20205228130432342676 5BeigelJHTomashekKMDoddLEMehtaAKZingmanBSKalilACHohmannEChuHYLuetkemeyerAKlineSLopez de CastillaDFinbergRWDierbergKTapsonVHsiehLPattersonTFParedesRSweeneyDAShortWRTouloumiGLyeDCOhmagariNOhMDRuiz-PalaciosGMBenfieldTFÃ¤tkenheuerGKortepeterMGAtmarRLCreechCBLundgrenJBabikerAGPettSNeatonJDBurgessTHBonnettTGreenMMakowskiMOsinusiANayakSLaneHCcollab: ACTT-1 Study Group MembersRemdesivir for the" exact="treatment" post="of Covid-19 - preliminary reportN Engl J Med2020NEJMoa2007764 6collab:"/>
  <result pre="GroupThe effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
  <result pre="influenza pneumonia: a future H5N1 treatment?Ann Intern Med200614559960916940336 12HungIFToKKLeeCKLeeKLChanKYanWWLiuRWattCLChanWMLaiKYKooCKBuckleyTChowFLWongKKChanHSChingCKTangBSLauCCLiIWLiuSHChanKHLinCKYuenKYConvalescent plasma" exact="treatment" post="reduced mortality in patients with severe pandemic influenza A"/>
  <result pre="a single centre experienceAntivir Ther20182361762229923831 17RajendranKKrishnasamyNRangarajanJRathinamJNatarajanMRamachandranAConvalescent plasma transfusion for the" exact="treatment" post="of COVID-19: Systematic reviewJ Med Virol2020[Epub ahead of print]"/>
  <result pre="print] 27AbolghasemiHEshghiPCheraghaliAMImani FooladiAABolouki MoghaddamFImanizadehSMoeini MalekiMRanjkeshMRezapourMBahramifarAEinollahiBHosseiniMJJafariNJNikpouraghdamMSadriNTazikMSaliSOkatiSAskariETabarsiPAslaniJSharifipourEJarahzadehMHKhodakarimNSalesiMJafariRShahverdiSClinical efficacy of convalescent plasma for" exact="treatment" post="of COVID-19 infections: Results of a multicenter clinical studyTransfus"/>
  <result pre="epitopes in humans elicited both enhancing and neutralizing effects on" exact="infection" post="in non-human primatesACS Infect Dis2016236137627627203 35collab: Food and Drug"/>
  <result pre="39HarvalaHMehewJRobbMLIjazSDicksSPatelMWatkinsNSimmondsPBrooksTJohnsonRGopalRRobertsDJZambonMcollab: NHS Blood and Transplant Convalescent Plasma Testing GroupConvalescent plasma" exact="treatment" post="for SARS-CoV-2 infection: analysis of the first 436 donors"/>
 </snippets>
</snippetsTree>
